January 23, 2018

FDA gets request to approve Pradaxa reversal agent idarucizumab

Big news! Boehringer Ingelheim has submitted an application to the FDA requesting accelerated approval for idarucizumab, the reversal agent for Pradaxa (dabigatran). See: Boehringer Ingelheim Submits Biologics License Application to FDA for Idarucizumab*, Investigational Specific Reversal Agent for Pradaxa® Additionally, they have submitted for marketing approval by Health Canada and the European Medicines Agency (EMA). See: Boehringer […]

Antidote for Eliquis Shows Positive Results

Here’s more good news about the upcoming antidote for Eliquis – see: Positive Results for Factor Xa Inhibitor Antidote: ANNEXA-A